EWM
REGN icon

Empirical Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Empirical Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,547
Closed -$1.81M – 702
2024
Q4 		$1.81M Buy
2,547
+474
+23% +$398K 0.05% 209
2024
Q3 		$2.18M Buy
2,073
+179
+9% +$199K 0.06% 180
2024
Q2 		$1.99M Sell
1,894
-5
-0.3% -$4.85K 0.06% 184
2024
Q1 		$1.83M Buy
1,899
+232
+14% +$221K 0.06% 187
2023
Q4 		$1.46M Buy
1,667
+196
+13% +$161K 0.05% 202
2023
Q3 		$1.21M Buy
1,471
+119
+9% +$93.5K 0.05% 208
2023
Q2 		$971K Buy
+1,352
New +$1.04M 0.04% 230
2022
Q2 		– Sell
-1,161
Closed -$811K – 519
2022
Q1 		$811K Sell
1,161
-876
-43% -$554K 0.04% 247
2021
Q4 		$1.29M Sell
2,037
-896
-31% -$551K 0.06% 175
2021
Q3 		$1.77M Buy
2,933
+563
+24% +$350K 0.1% 125
2021
Q2 		$1.32M Buy
2,370
+529
+29% +$268K 0.08% 155
2021
Q1 		$871K Buy
1,841
+705
+62% +$343K 0.07% 173
2020
Q4 		$549K Buy
+1,136
New +$613K 0.04% 237

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Empirical Wealth Management's REGN Position: Q1 2025 in Review

Empirical Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 2,547 shares — an estimated $1.81M sold.

Empirical Wealth Management first reported a position in REGN in Q4 2020 and held it in 13 quarters. The position peaked at $2.18M in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Empirical Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Empirical Wealth Management sold 2,547 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $1.81M.
  • Empirical Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Empirical Wealth Management's Regeneron Pharmaceuticals position peaked at $2.18M in Q3 2024.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Empirical Wealth Management's 13F filing for Q1 2025, filed 8 May 2025.